Repare Therapeutics

company

About

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$68M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2016
Number Of Employee
51 - 100
Operating Status
Active

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$150.50M
Repare Therapeutics has raised a total of $150.50M in funding over 2 rounds. Their latest funding was raised on Sep 4, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 4, 2019 Series B $82.50M 2 Detail
Jun 22, 2017 Series A $68M 2 Versant Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Repare Therapeutics is funded by 2 investors. UBS Oncology Impact Fund and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
UBS Oncology Impact Fund Series B
Versant Ventures Series B